Predictive factors related to the efficacy of Golimumab in patients with rheumatoid arthritis

6Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

In order to investigate the predictive factors related to clinical efficacy and radiographic progression at 24 weeks by looking at the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 including baseline characteristics in patients with rheumatoid arthritis (RA) treated with golimumab, serum concentrations of TNF-α and IL-6 were analyzed every 4 weeks up to 24 weeks in 47 patients treated with golimumab. Baseline levels of the Disease Activity Score 28 C-reactive protein (DAS28-CRP) and Simplified Disease Activity Index (SDAI) scores were also assessed. Radiographic progression using the van der Heijde-modified Sharp (vdH-S) score was assessed in 29 patients. Multiple regression analyses related to the DAS28-CRP score and delta total sharp score at 24 weeks was undertaken using the baseline characteristics of patients and serum concentrations of matrix metallo-proteinase (MMP)-3, TNF-α, and IL−6. The DAS28-CRP score and SDAI decreased significantly at 4 weeks up to 24 weeks compared with baseline. Serum levels of TNF-α were not changed significantly up to 24 weeks compared with baseline, but those of IL-6 decreased significantly at 4 weeks up to 8 weeks. Multiple regression analyses showed that disease duration and serum levels of MMP-3 were related significantly to the DAS28-CRP score at 24 weeks. Radiographic progression was related significantly to disease duration with regard to joint space narrowing and bone erosion. However, serum levels of TNF-α and IL-6 were not correlated significantly with the DAS28-CRP score and radiographic progression. These data suggest that decreasing serum levels of IL-6 significantly, MMP-3, and disease duration are predictive factors for RA activity in patients taking golimumab.

References Powered by Scopus

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

19360Citations
N/AReaders
Get full text

Therapeutic criteria in rheumatoid arthritis

2501Citations
N/AReaders
Get full text

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

1665Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases

83Citations
N/AReaders
Get full text

The use of platelet-rich plasma in studies with early knee osteoarthritis versus advanced stages of the disease: a systematic review and meta-analysis of 31 randomized clinical trials

15Citations
N/AReaders
Get full text

Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kanbe, K., Chiba, J., Inoue, Y., Taguchi, M., & Yabuki, A. (2015). Predictive factors related to the efficacy of Golimumab in patients with rheumatoid arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 8, 25–32. https://doi.org/10.4137/CMAMD.S22155

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

46%

Researcher 5

38%

Professor / Associate Prof. 2

15%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

71%

Biochemistry, Genetics and Molecular Bi... 2

14%

Pharmacology, Toxicology and Pharmaceut... 1

7%

Nursing and Health Professions 1

7%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 18

Save time finding and organizing research with Mendeley

Sign up for free